top of page
  • Jonathan Poyer

Biotech Capital Markets Still Active - 3 Years in a Row of Negative Performance for the XBI in Play



Week Ending November 17th, 2023


  • Biotech: 2 Transactions (1 PIPE and 1 RD ) totaling just over $200 Million

  • Med Tech: No Current Week Transactions



2023 YTD


  • 159 Biotech transactions totaling just under $24 Billion v. 2022: 144 Biotech transactions totaling just under $18 Billion

  • 18 Med Tech transactions totaling just over $1 Billion v. 2022: 10 Med Tech transactions just under $900 Million



Private Transactions:


  • Biotech: 220 Transactions / 67 European Transactions

  • Med Tech: 126 US Transactions / 37 European Transactions



November Major Transactions:


  • Astellas Pharma acquired Proprella Therapeutics - $175M

  • Ajinomoto acquired Forge Biologics - $554M



October Major Transactions:


  • Roche aqcuired Telavant - $7.1B

  • Bristol Myers Squibb aquired Mirati Therapeutics - $4.8B; $58/Share

  • AbbVie acquired Mitokinin - $110M

  • Kyowa Kirin acquired Orchard Therapeutics - $387M; $16/Share

  • Eli Lilly acquired Point Biopharma - $1.4B; $12.50/Share


5 views0 comments

Comments


bottom of page